• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hydrocortisone rapidly and significantly reduces the IL-6 level in blood and lungs of patients with COVID-19-related ARDS.

作者信息

Guillon Antoine, Jouan Youenn, Kassa-Sombo Arthur, Paget Christophe, Dequin Pierre-François

机构信息

Intensive Care Unit, Tours University Hospital, 2 Bd Tonnellé, 37044, Tours Cedex 9, France.

Research Center for Respiratory Diseases, INSERM U1100, University of Tours, Tours, France.

出版信息

Crit Care. 2024 Mar 28;28(1):101. doi: 10.1186/s13054-024-04887-2.

DOI:10.1186/s13054-024-04887-2
PMID:38549157
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10976785/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a44a/10976785/7390468f0f3b/13054_2024_4887_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a44a/10976785/7390468f0f3b/13054_2024_4887_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a44a/10976785/7390468f0f3b/13054_2024_4887_Fig1_HTML.jpg

相似文献

1
Hydrocortisone rapidly and significantly reduces the IL-6 level in blood and lungs of patients with COVID-19-related ARDS.氢化可的松能迅速且显著降低新型冠状病毒肺炎相关急性呼吸窘迫综合征患者血液和肺部中的白细胞介素-6水平。
Crit Care. 2024 Mar 28;28(1):101. doi: 10.1186/s13054-024-04887-2.
2
[Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19].[关于阿那白滞素用于新型冠状病毒肺炎继发急性呼吸窘迫综合征的建议]
Reumatol Clin (Engl Ed). 2021 Jun-Jul;17(6):309-312. doi: 10.1016/j.reuma.2020.04.009. Epub 2020 Apr 27.
3
Comparison of the efficacy of equivalent doses of dexamethasone, methylprednisolone, and hydrocortisone for treatment of COVID-19-related acute respiratory distress syndrome: a prospective three-arm randomized clinical trial.比较等效剂量地塞米松、甲泼尼龙和氢化可的松治疗 COVID-19 相关急性呼吸窘迫综合征的疗效：一项前瞻性三臂随机临床试验。
Wien Med Wochenschr. 2023 Apr;173(5-6):140-151. doi: 10.1007/s10354-022-00993-4. Epub 2023 Jan 9.
4
COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- A retrospective observational study.COVID-19 和非 COVID-19 导致的急性呼吸窘迫综合征患者对低剂量类固醇的反应明显不同——一项回顾性观察研究。
J Crit Care. 2021 Apr;62:46-48. doi: 10.1016/j.jcrc.2020.11.012. Epub 2020 Nov 21.
5
COVID-19 infection: an overview on cytokine storm and related interventions.COVID-19 感染：细胞因子风暴及相关干预措施概述。
Virol J. 2022 May 26;19(1):92. doi: 10.1186/s12985-022-01814-1.
6
A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19.一项关于静脉注射α-1抗胰蛋白酶治疗新型冠状病毒肺炎继发急性呼吸窘迫综合征的随机、双盲、安慰剂对照试验。
Med. 2022 Apr 8;3(4):233-248.e6. doi: 10.1016/j.medj.2022.03.001. Epub 2022 Mar 11.
7
High Induction of IL-6 Secretion From hUCMSCs Optimize the Potential of hUCMSCs and TCZ as Therapy for COVID-19-Related ARDS.高诱导 hUCMSCs 分泌 IL-6 优化 hUCMSCs 和 TCZ 治疗 COVID-19 相关 ARDS 的潜能。
Cell Transplant. 2021 Jan-Dec;30:9636897211054481. doi: 10.1177/09636897211054481.
8
Lung targeted liposomes for treating ARDS.用于治疗 ARDS 的肺部靶向脂质体。
J Control Release. 2022 Jun;346:421-433. doi: 10.1016/j.jconrel.2022.03.028. Epub 2022 Mar 28.
9
Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction.COVID-19 相关急性呼吸窘迫综合征和肺外多器官功能障碍患者炎症细胞因子风暴中的特定细胞因子。
Virol J. 2021 Jun 4;18(1):117. doi: 10.1186/s12985-021-01588-y.
10
Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis.两种 COVID-19 相关急性呼吸窘迫综合征表型低氧血症的发病机制：血栓形成和止血的见解。
Shock. 2022 Jan 1;57(1):1-6. doi: 10.1097/SHK.0000000000001825.

引用本文的文献

1
Clinical management of sepsis-associated acute respiratory distress syndrome: current evidence and future directions.脓毒症相关急性呼吸窘迫综合征的临床管理：当前证据与未来方向
Front Med (Lausanne). 2025 May 26;12:1531275. doi: 10.3389/fmed.2025.1531275. eCollection 2025.
2
Association of Vitamin D Supplementation with Glutathione Peroxidase (GPx) Activity, Interleukine-6 (IL-6) Levels, and Anxiety and Depression Scores in Patients with Post-COVID-19 Condition.维生素D补充剂与新冠后综合征患者谷胱甘肽过氧化物酶（GPx）活性、白细胞介素-6（IL-6）水平以及焦虑和抑郁评分的关联
Int J Mol Sci. 2025 May 10;26(10):4582. doi: 10.3390/ijms26104582.
3

本文引用的文献

1
Lung compartmentalization of inflammatory biomarkers in COVID-19-related ARDS.新型冠状病毒肺炎相关急性呼吸窘迫综合征中炎症生物标志物的肺部分布
Crit Care. 2021 Mar 24;25(1):120. doi: 10.1186/s13054-021-03513-9.
2
A living WHO guideline on drugs for covid-19.关于新冠病毒药物的世界卫生组织实用指南。
BMJ. 2020 Sep 4;370:m3379. doi: 10.1136/bmj.m3379.
3
Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients.在重症 COVID-19 患者中非常规 T 细胞的表型和功能改变。
Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action.
重新利用现有药物治疗新冠病毒病/严重急性呼吸综合征冠状病毒2：药理作用及作用机制综述
Heliyon. 2024 Aug 11;10(16):e35988. doi: 10.1016/j.heliyon.2024.e35988. eCollection 2024 Aug 30.
4
Revisiting the COVID-19 Pandemic: Mortality and Predictors of Death in Adult Patients in the Intensive Care Unit.重新审视新冠疫情：重症监护病房成年患者的死亡率及死亡预测因素
Life (Basel). 2024 Aug 19;14(8):1027. doi: 10.3390/life14081027.
J Exp Med. 2020 Dec 7;217(12). doi: 10.1084/jem.20200872.
4
Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.COVID-19 重症患者中氢化可的松对 21 天死亡率或呼吸支持的影响：一项随机临床试验。
JAMA. 2020 Oct 6;324(13):1298-1306. doi: 10.1001/jama.2020.16761.